key: cord-0800397-bgkw74y4
authors: Narowski, Tara M.; Raphel, Kristin; Adams, Lily E.; Huang, Jenny; Vielot, Nadja A.; Jadi, Ramesh; de Silva, Aravinda M.; Baric, Ralph S.; Lafleur, John E.; Premkumar, Lakshmanane
title: SARS-CoV-2 mRNA Vaccine Induces Robust Specific and Cross-reactive IgG and Unequal Neutralizing Antibodies in Naïve and Previously Infected Recipients
date: 2022-01-20
journal: Cell Rep
DOI: 10.1016/j.celrep.2022.110336
sha: 8afefc040b9ff455c656fe3e61bdb2d1140ae207
doc_id: 800397
cord_uid: bgkw74y4

Understanding vaccine-mediated protection against SARS-CoV-2 is critical to overcoming the global COVID-19 pandemic. We investigate mRNA vaccine-induced antibody responses against the reference strain, seven variants, and seasonal coronaviruses in 168 healthy individuals at three-time points: before vaccination, after the first, and after the second doses. Following complete vaccination, both naïve and previously infected individuals developed comparably robust SARS-CoV-2 spike antibodies and variable levels of cross-reactive antibodies to seasonal coronaviruses. However, the strength and frequency of SARS-CoV-2 neutralizing antibodies in naïve individuals were lower than in previously infected individuals. After the first vaccine dose, 1/3rd of previously infected individuals lacked neutralizing antibodies; this was improved to 1/5th after the second dose. In all individuals, neutralizing antibody responses against the Alpha and Delta variants were weaker than against the reference strain. Our findings support future tailored vaccination strategies against emerging SARS-CoV-2 variants as mRNA-vaccine-induced neutralizing antibodies are highly variable among individuals.

The SARS-CoV-2 virus causes a spectrum of disease from asymptomatic to severe forms with high mortality. The nucleocapsid protein encapsulating viral RNA and the surface exposed spike protein are the primary targets of human antibodies. The spike protein of SARS-CoV-2 mediates virus attachment and entry into host cells. It comprises a highly variable S1 segment, which harbors the Nterminal domain (NTD) and the receptor-binding domain (RBD), and a more conserved S2 segment which includes the fusion peptide and heptad repeats required for virus fusion to host cells. Neutralizing antibody response is at present the best correlate of protection (Earle et al., 2021) . However, the adaptive immune response to SARS-CoV-2 infection is variable (Chvatal-Medina et al., 2021; Gao et al., 2021; Sette and Crotty, 2021) . RBD accounts for ~90% of the neutralizing activity in SARS-CoV-2 immune sera (Piccoli et al., 2020; Greaney, Loes, Crawford, et al., 2021) . RBD-specific antibodies target distinct antigenic sites and exert neutralizing activity principally by interfering with spike protein interactions with its cognate receptor, angiotensin-converting enzyme 2 (ACE2). A subset of the NTDspecific antibody also neutralizes SARS-CoV-2 by targeting a supersite, possibly preventing proteolytic activation, membrane fusion, or spike protein interactions with an auxiliary receptor (McCallum et al., 2021) . The spike protein has been targeted in most SARS-CoV-2 vaccines under development and in those approved and currently being administered worldwide.

The recent effort to achieve widespread vaccination against SARS-CoV-2 has left in its wake a host of questions about whether the vaccine can protect against SARS-CoV-2 infection and whether the vaccine can boost immunity in previously infected people (Fakhroo, Al Thani and Yassine, 2020; LoPresti et al., 2020; Miller et al., 2020) . Infection with four human endemic coronaviruses (HCoVs; emergence of new, increasingly infectious and virulent SARS-CoV-2 variants is causing significant concern in global human health. Prior to the dominance of the Delta variant (B.1.617.2), the US SARS-CoV-2 Interagency Group had classified the variants circulating in the United States, including Alpha (B.1.1.7), Gamma (P.1), Beta (B.1.351), and Epsilon strains (B.1.429 and B.1.427) , as variants of concern (VOC). However, with the emergence of the Delta variant (del Rio, Malani and Omer, 2021) , other circulating variants sustained reductions in transmission, and are now termed 'variants being monitored' (VBM), while the Delta variant is at present the sole VOC in the US. As illustrated by the Delta variant, more infectious strains of the virus can rapidly become dominant (Mishra et al., 2021) , displacing other strains with potentially different levels of virulence and host immune profiles. SARS-CoV-2 variants have accumulated key mutations, particularly in the spike protein within the NTD and the RBD, and significant concerns are developing around the efficacy of currently available treatments and vaccines. Understanding factors that underly the level of defense provided by SARS-CoV-2 vaccines against the reference WIV04 strain and circulating variants is an urgent priority. As seen with the Delta variant, novel strains that have different virulence and vaccine susceptibility can become rapidly dominant, potentially changing the degree of protection provided by the currently available vaccines (del Rio, Malani and Omer, 2021; Zella et al., 2021) .

We previously reported that seroprevalence among a cohort of uniformly exposed emergency department health care providers was about 5% after the first peak of the infection in Washington, DC, in the late Spring of 2020 (Murakami et al., 2021) . PCR confirmed documented SARS-CoV-2 infection increased to about 11% in this cohort of 237 participants by the end of 2020, an incidence of infection in line with health care providers generally in North America (Sokal et al., 2021) . Here we investigate the longitudinal antibody response at three time points to the reference Wuhan strain (WIV04), seven other variants including the currently circulating dominant Delta variant, and four endemic Coronaviruses (HCoVs). Sample collection occurred during the Spring of 2020 after the pandemic's first peak; January of 2021 in the period immediately following the roll-out of the mRNA vaccines; and after the majority of the cohort had been fully vaccinated in early March 2021. By combining PCR and J o u r n a l P r e -p r o o f serology test results, we first determined that the previous exposure to SARS-CoV-2 irrespective of the symptoms within this cohort is about 14% before vaccination. We then evaluated SARS-CoV-2 mRNA vaccine-induced antibody isotypes, the magnitude of spike-specific and cross-reactive antibodies, and neutralizing antibodies against the reference WIV04 strain and circulating variants.

and March 2021, we enrolled 237 healthcare workers in a large tertiary academic medical center (George Washington University, United States), to estimate baseline serostatus and study antibody response after doses 1 and 2 of an mRNA vaccine among previously infected and naïve individuals ( Figure S1 and Table S1 ). Overall, participants were young (median age=30 years) and healthy (82.1% reported no chronic medical conditions). Of 237 healthcare workers, 161 participants received the Pfizer-BioNTech mRNA vaccine (BNT162b2), and 7 participants received then Moderna mRNA-1273 vaccine. Both of these vaccines use mRNA to induce the expression of stabilized full-length SARS-CoV-2 spike protein (Angeli et al., 2021) . We collected a total of 424 longitudinal samples from the 237 health care workers. This was done pre-vaccination (n=136 collected 6 months before vaccination), after dose 1 (n=149 collected between 6 -28 days of vaccination [median 21 days]), and after dose 2 (n=139 collected within 66 days of vaccination [median 54 days]). At the start of the enrollment in June 2020, 7 participants were seropositive, and between June 2020 and Dec 2020, 19 additional participants experienced symptomatic, mild SARS-CoV-2 infection, detected by RT-PCR. None of the infected HCP in this study experienced severe disease requiring hospitalization. To determine the SARS-CoV-2 serostatus of all the participants, we measured SARS-CoV-2 nucleocapsid antibodies in pre-vaccine and dose 1 samples and Spike RBD antibodies before vaccination ( Figure S1 ). We stratified the 237 participants as 35 seropositive and 202 as seronegative by combining RT-PCR and serology test results ( Figure S1 ). Among the 168 mRNA vaccine recipients, 20 were previously infected, and 148 were naïve. Analysis of self-reported symptoms following vaccination indicated that naïve J o u r n a l P r e -p r o o f individuals tended to experience fewer symptoms following both vaccine doses than previously infected individuals ( Figures S2 and S3 ).

In symptomatic SARS-CoV-2 infections, IgG, IgM, and IgA antibodies are typically developed after 9 days post symptom onset (Sette and Crotty, 2021) . To understand the antibody response following the doses 1 and 2 mRNA vaccines, we measured the SARS-CoV-2 antibody isotypes against full spike and RBD antigens ( Figure 1 ). Among the naïve, antibody levels were low up to 7 days, and IgG antibodies to full spike and RBD antigens seroconverted in >95% of the participants by day 8 (Figures 1A and D) . The predominant response was for the IgG antibodies in both naïve and previously infected participants after doses 1 and 2. Among naïve individuals, IgM and IgA antibodies were higher after the first dose than the second dose ( Figure 1G and H). In previously infected individuals, IgM levels were generally lower than the naïve individuals. However, IgA levels in the previously infected individuals were comparable to the naïve individuals after dose 1, and was unchanged after dose 2 ( Figure 1H ).

Having observed that the IgG antibodies are dominant, we compared the magnitude of IgG response after doses 1 and 2 in titration ELISA assays against full spike, RBD, and NTD antigens ( Figure 2 ). The spike IgG antibody levels, measured by the area under the curve in titration experiments, was robustly boosted among the previously infected participants following dose 1, but this response varied in some individuals (Figure 2A -C). The variation of the spike IgG antibodies after the first dose was higher in naïve than the previously infected individuals. After dose 2, IgG response to spike antigens was highly focused, and the antibody levels were comparable between naïve and the previously infected individuals. The magnitude of RBD antibodies correlated well to NTD and the full spike antibodies in both groups ( Figure 2E and F).

We and others have previously shown that the levels of RBD binding antibodies correlated to the SARS-CoV-2 neutralizing antibody titers (Premkumar et al., 2020; Wajnberg et al., 2020; Dogan et al., 2021; Freeman et al., 2021) . To understand the relationship between neutralizing antibodies and spike binding antibodies after mRNA vaccination, we measured live virus SARS-CoV-2 neutralizing titers in 37 paired samples comprising 15 previously infected and 22 naïve individuals after vaccine doses 1 and 2 ( Figure 3 ). Among previously infected and naïve vaccine recipients, we observed a robust correlation between SARS-CoV-2 neutralizing antibodies and the levels of the spike RBD and NTD IgG binding antibodies and a modest correlation with full-spike binding IgG antibodies ( Figure 3C and D).

We also noticed a moderate-to-high correlation between the neutralizing antibody levels and RBD and full-spike serum IgA antibodies among previously infected vaccine recipients.

Strikingly, about 85% (17/20) of the naïve did not develop detectable levels of neutralizing antibodies >15 days after dose 1 ( Figure 3A and C), and about 50% (9/19) of those naive vaccine recipients neutralizing antibodies was not detectable even after dose 2 between 20 and 66 days ( Figure   3B and D). In contrast, 66% (10/15) of previously infected individuals developed neutralizing antibodies after dose 1, and after dose 2, 80% (12/15) of the previously infected had neutralizing antibodies ( Figure   3C ). Even though both naive and previously infected individuals developed similar levels of spike binding antibodies after dose 2, the mean and median neutralizing antibody levels among the naive recipients were at least ten and four folds weaker than the previously infected vaccine recipients (Cf. Figure 3C and 3D). Overall, the relationship between spike binding and SARS-CoV-2 neutralizing antibodies typically improved between doses 1 and 2, indicated by the increase in correlation and decreased interquartile range (IQR), and followed non-monotonic relationships, which we divided into three groups. In group 1, neutralizing antibodies were undetectable after dose 1 and remained undetectable or became detectable after dose 2. In group 2, neutralizing antibody response declined between doses 1 and 2, whereas neutralizing antibody response in group 3 was detectable after dose 1 and generally improved after dose 2. In group 1, individuals in the 50-70 age range poorly developed J o u r n a l P r e -p r o o f binding and functional antibodies even after complete vaccination ( Figure S4 ). In comparison, individuals in the 20-49 age range from this group also responded poorly after the first dose, but their antibody levels relatively significantly improved after the second dose. In group 2, the decline in neutralizing antibody response between doses 1 and 2 varied from 20% to 80% among previously infected and naïve participants. In group 3, the improvement in the neutralizing antibody response between doses 1 and 2 was 2-fold or less. the neutralizing activity for the reference WIV04 strain and the variants after doses 1 and 2 among naive and previously infected individuals in a multiplex surrogate neutralization assay ( Figure 4A and B). The multiplex surrogate neutralization assay simultaneously measured antibodies that can block the interaction between RBD and ACE2 in a panel of spike antigens from the reference WIV04 strain and the above seven novel viral variants. The percentage of the ACE2 blocking antibodies in the surrogate neutralization assay with 100X diluted sera robustly correlated to the neutralizing antibody titers obtained from the BSL-3 SARS-CoV-2 neutralization assay ( Figure 4C ). In general, previously infected vaccine recipients displayed higher spike-ACE2 blocking activity compared to the naïve vaccine recipients. The magnitude of RBD binding antibodies correlated with the spike-ACE2 blocking activity against the reference strain and followed a non-monotonic relationship across the three groups as observed for the live virus neutralization assay ( Figure 3 ). The spike-ACE2 blocking activity of Delta and other variants in naïve and pre-exposed individuals was an average 20-30% weaker than the ACE2 blocking activity of the mRNA vaccine-reference strain WIV04 after dose 2 ( Figure 4D and E). Overall, people with high RBD binding antibodies also developed better ACE2 blocking activity and vice versa ( Figure 4D and E).

J o u r n a l P r e -p r o o f mRNA vaccine induces higher levels of endemic HCoV cross-reactive antibodies in previously infected than in naïve individuals. All participants in our cohort have been previously exposed to more than one human endemic CoVs. The development of cross-reactive antibodies to human endemic CoVs was reported previously in hospitalized patients with severe SARS-CoV-2 symptoms (Guo et al., 2021) . We, therefore, measured longitudinal antibody levels against the full spike antigens from the reference SARS-CoV-2 and the four-human endemic CoVs using a titration ELISA with the samples collected at pre-vaccination and after doses 1 and 2 from previously infected and naïve individuals ( Figure 5 ). While most vaccine recipients developed antibodies to SARS-CoV-2 as expected, we observed that some previously infected and naïve individuals developed strong cross-reactive antibodies to HCoV spike antigens. The cross-reactive antibody levels were more robust after dose 1 against the -HCoVs (OC43 and HKU-1, Figure 5B -C, G-H and K) than -HCoVs (NL63 and 229E, Figure 5D -E, I-J and K). Similarly, the cross-reactive antibody levels against HCoVs were more pronounced in previously infected individuals than the naïve individuals, marked by a sharper rise after dose 1 followed by a noticeable decline between the first and second dose ( Figure 5) . Notably, the levels of cross-reactive antibodies induced after vaccination were highly correlated among HCoVs, indicating that the cross-reactive antibodies are most likely targeting conserved epitope(s) shared among the spike protein ( Figure 5L ).

Our study on binding and neutralizing antibody response after two doses of mRNA vaccines in 168 naïve and previously infected individuals provides novel insights into vaccine-induced immunity against the reference strain and variants. Similar to a few independent studies, we observed comparable levels of IgG responses to spike RBD and NTD following complete vaccination in both naïve and previously infected recipients (Cho et al., 2021; Ebinger et al., 2021; Gobbi et al., 2021) .

However, our study demonstrates that the vaccine-induced neutralizing antibody response varies among these individuals.

We and others have previously shown that RBD antibody levels correlate well to the magnitude of the neutralizing antibodies in symptomatic SARS-CoV-2 infections (Premkumar et al., 2020; Röltgen et al., 2020; Wajnberg et al., 2020; Dogan et al., 2021; Freeman et al., 2021) . Among convalescent plasma donors (Markmann et al., 2021) with binding anti-RBD IgG titers over 1:160, 95% developed live virus-neutralization. By contrast, after full vaccination about 2/5 th of the naïve and 1/5 th of the previously infected vaccine recipients in our cohort-even though mean binding anti-RBD titers were significantly higher than 1:160--did not develop detectable levels of neutralizing antibodies in a live virus-neutralization assay. These observations suggest that antibodies developed after mRNA vaccination and natural SARS-CoV-2 infection differ. Recently, Greaney et al., reported that mRNA-1273 elicited RBD-focused antibody response that targeted a broader range of epitopes than those produced by natural infection (Greaney, Loes, Gentles, et al., 2021) , suggesting one possible basis for the observed difference. What remains unexplained is the disparity in neutralizing antibodies between the previously infected in our cohort, and that observed in convalescent plasma donors. One difference between these two groups is that the previously infected from our cohort also received two doses of an mRNA vaccine, while the data reported in the convalescent plasma group was collected before any vaccines were widely available. At present the significance of this remains unclear.

Threshold levels of neutralizing antibodies for SARS-CoV-2 immunity have yet to be established, and even relatively low levels of neutralizing antibodies have been associated with protection in nonhuman primate models (Gao et al., 2020) . Nonetheless, the lack of detectable levels of neutralizing antibodies in 40% of naïve participants is concerning and differs from the previous reports (Ebinger et al., 2021; Naaber et al., 2021; Terpos et al., 2021) . The difference between our results and other studies may indicate the importance of assay harmonization and validation of surrogate neutralization titers with authentic live virus-neutralization assays. Edinberger et al., have utilized a particular threshold of IgG level and % ACE2 binding inhibition activity as a surrogate for a plaque reduction neutralization test and reported that previously infected and naive individuals develop similar ACE2 blocking activities after two doses of mRNA vaccine (Ebinger et al., 2021) . A study of 308 healthy individuals reported J o u r n a l P r e -p r o o f persistent neutralizing response several months after vaccination by testing the samples at low dilution in an ACE2 binding inhibition assay (Terpos et al., 2021) . Nevertheless, other factors may also contribute to the differences between our observations and other studies, including sample collection after vaccination, amount of vaccine dose, dosing intervals, virus strain (WIV04 strain vs WIV04 strain with D614G mutation), and participant demographics. Our study utilized the WIV04 reference strain in a BSL3 live virus-neutralization assay and a multiplex ACE2 binding inhibition assay with a broader dynamic range as well as evaluated the correlation between these assays within the study subjects.

The samples in our study were analyzed between 1 and 4 weeks after dose 1, and between 3 and 9 weeks after dose 2 of the BNT162b2 vaccine. Naaber et al., reported significant ACE2 blocking antibodies 1 week after dose 2 (median relative OD of 0.64 compared to 0.97 at baseline) that declined after 12 weeks (median relative OD 0.75) among BNT162b2 vaccine recipients (Naaber et al., 2021) .

A recent study involving 8 subjects who received the mRNA-1273 vaccine reported persistent neutralizing antibodies 6 months after the second dose. Notably, mRNA-1273 vaccine recipients received two 100-μg doses at 28-day intervals whereas BNT162b2 vaccine recipients received 30-µg doses at 21-day intervals (Pegu et al., 2021) .

In our study, we observed that neutralizing antibody responses to vaccination fell into one of three groups. Group 1, showed weak neutralizing antibody development after the first vaccine dose, and in the aggregate, an inadequate neutralizing Ab response after complete vaccination. Group 2, showed an initial strong and protective neutralizing antibody response followed by a decline after the second dose. Group 3, showed a modest initial response followed by increased and generally protective levels of neutralizing antibody after the second vaccine dose. Understanding any biological basis underlying the different vaccination responses in these groups could broaden our understanding of those at risk for infection despite vaccination. As reported elsewhere (Collier et al., 2021) , age appears to be negatively correlated with binding and neutralizing antibody development in our cohort ( Figure   S4 ). There may be factors other than age that are important to this phenomenon.

Of particular interest is group 2 with the highest level of neutralizing antibody after the first vaccine dose, subsequently declining to below that of group 3 after the second dose. The experience of this group explains to some extent the lower than expected levels of neutralizing antibody after full vaccination in our cohort. It does not seem likely that protective vaccine-mediated immunity having been established in group 2 after dose 1 became inadequate after dose 2, even though measured levels of neutralizing antibodies declined. That being said, evidence of decreasing neutralizing antibody between the first and second vaccine doses has also been observed in previous reports (Cho et al., 2021) , indicating a decline of transient antibody levels and/or inadequate dosing intervals. Recent studies have shown that extending the dosing interval to between 6 and 12 weeks have resulted in higher levels of neutralizing antibodies after dose 2 compared with conventional 3-to 4-week regimen (Payne et al., 2021) . If the pattern of vaccine response observed in group 2 in our cohort is reflected in larger populations, extending the dosing interval may be considered for this group.

Multiple reports have also surfaced recently that previously infected individuals may not need or benefit from a second dose of an mRNA vaccine (Gobbi et al., 2021; Mazzoni et al., 2021; Padoan et al., 2021; Perez Marc, Alvarez-Paggi and Polack, 2021; Vicenti et al., 2021; Wise, 2021) . Our data, by contrast, shows that 1/3 rd of previously infected individuals did not produce detectable levels of neutralizing antibodies after the first dose ( Figure 3A , Group 1); after the second dose, however, 40% of these non-responders produced neutralizing antibodies. A lack of increased spike binding antibody level after the second dose in those previously infected with SARS-CoV-2 has also been cited as evidence that the second dose is unnecessary (Gobbi et al., 2021; Goel et al., 2021; Zipeto et al., 2021) .That being said, and while data is scanty, clinical evidence does not yet exist that vaccination of the previously infected confers more immunity to reinfection than does vaccination of naïve recipients to primary infection (Cho et al., 2021; Teran et al., 2021) . Moreover, while elevated levels of neutralizing antibodies are considered highly protective (Khoury et al., 2021) , some reports have questioned this relationship (Bradley et al., 2021) , and suggested that other biomarkers may better predict SARS-CoV- 

Protection following vaccination has been noted in those who have not yet produced significant neutralizing antibodies, suggesting other possible protective mechanisms. One possibility involves nonneutralizing antibodies which mediate viral elimination through antibody Fc fragment binding to host effector cells (Beaudoin-Bussières et al., 2021) . At present, though, neutralizing antibodies remains the best-known correlate of protection (Earle et al., 2021) against SARS-CoV-2 infection.

Immunity against SARS-CoV-2 variants, including the now dominant Delta variant and the newly emerging Omicron variant, is a topic of great interest. Our data demonstrated that the current mRNA vaccine-mediated neutralizing antibodies are effective against the Alpha and the Delta variants and our observations are consistent with other reports (Abu-Raddad, Chemaitelly and Butt, 2021). It has been argued that 'affinity maturation' can over time produce 'broadly neutralizing antibodies' (BNABs) with the ability to provide sterilizing immunity based on high affinity for conserved epitopes among variant pathogens (Sprenger et al., 2020; Muecksch et al., 2021) . 'Persistent' exposure to pathogen antigens is thought to underlie the process of affinity maturation and the development of BNABs. It follows from this that optimized (Sprenger et al., 2020) timing of SARS-CoV-2 spike antigen exposure through booster vaccinations with the currently approved mRNA vaccines may be a route to increase resistance to SARS-CoV-2 variants.

In support of this idea there are reports (Leier et al., 2021) of the development of adequate neutralizing antibodies against SARS-CoV-2 variants following administration of mRNA vaccines to previously infected subjects, suggesting that repeated exposure (beyond that achieved by two doses of the vaccine) may contribute to maintaining competent immunity against SARS-CoV-2 variants.

However, it has also been reported that binding and neutralization of the ACE2 binding site by the two most frequently elicited human antibody families (IGHV3-53/3-66 and IGHV1-2-- Figure 4C ) was significantly abrogated by the mutations observed in the circulating variants (Yuan et al., 2021) . One possible explanation for this apparent paradox is that an initial polyclonal response during the relatively short period after vaccination (~2 months) is effective against circulating variants. It may be the case that as the immune response matures in vaccinated subjects, and the polyclonal response wanes, J o u r n a l P r e -p r o o f susceptibility to the variants could widen, raising the question of whether in the future variant-focused re-vaccination with modified vaccines will become necessary?

There are concerns (Lawton, 2021; Noori, Nejadghaderi and Rezaei, 2021) regarding potential problems with the effectiveness of such modified vaccines; however, whether or not the current vaccine regimen, or repeated doses of the existing vaccines will induce BNABs against currently circulating SARS-CoV-2 variants, remains in question. In this regard it is worth noting that a potent cross-reactive antibody (Moyo-Gwete et al., 2021) derived from a SARS-CoV-2-variant epitope has recently been reported, suggesting that modified vaccines produced in this fashion may prove broadly effective. While at present vaccine-mediated immunity against the currently dominant Delta variant appears effective, constant mutation by the virus in large unvaccinated populations in which SARS-CoV-2 transmission continues unabated suggests the potential for evolving a highly divergent variant such as Omicron against which the current vaccines may be less effective (Callaway, 2021; Krause et al., 2021; Yuan et al., 2021) .

Recent studies have reported declining of SARS-CoV-2 neutralizing antibodies > 6 months after receipt of the second dose of mRNA vaccine, provoking debate over mass booster vaccination (Goldberg et al., 2021) . Widely administered booster immunizations against reference/variants will expose a previously vaccinated and sensitized population to risk of vaccine reaction with attendant risks and discomforts (Remmel, 2021) . Our data shows that previous SARS-CoV-2 exposure either from infection or vaccination results in greater symptoms in response to a second exposure to SARS-CoV-2 antigens; however, a recent small scale study which looked at booster vaccinations with one of the two mRNA vaccines reported no more than moderate symptoms in just 15% of subjects (Wu et al., 2021) .

Along with neutralizing IgG, the production of anti-spike IgA in the airways has been proposed to prevent SARS-CoV-2-reinfection (Cervia et al., 2021; Dispinseri et al., 2021) . Mucosal immunity plays a vital role in viral respiratory infections; IgA dominates early immune response with development J o u r n a l P r e -p r o o f of mucosally oriented plasmablasts in natural SARS-CoV-2 infection (Sterlin et al., 2021) . Neutralizing mucosal IgA has been associated with milder SARS-COV-2, while circulating neutralizing IgG with more severe disease (Butler et al., 2021) . The importance of mucosal protection in SARS-COV-2 has led some to advocate for nasally administered vaccines that induce more robust mucosal IgA responses (Z. . In our study parenterally delivered mRNA vaccines induce high levels of anti-Spike IgG-similar to what is seen in severe disease. IgA production, by contrast, is induced in more modest quantities, comparable to what is seen in mild disease (Röltgen et al., 2021) . Induction of strong IgG and, low IgA levels in naïve patients after receiving one of the two mRNA vaccines has also been recently reported in other independent studies (Danese et al., 2021) . Serum IgA levels are not a direct measure of secretory IgA levels, since systemic IgA are predominantly made of monomeric IgA1 subclass, and mucosal IgA is a polymeric IgA2 subclass (Crago et al., 1984) . However, induction of mucosal IgA after parenteral mRNA vaccination has been reported (Ketas, Chaturbhuj, Portillo, et al., 2021) . Our data shows that after full vaccination, spike IgA levels in serum correlated better to the levels of neutralizing antibodies in previously infected vaccine recipients than among naïve recipients, a phenomenon that may be related to a more mature immune response in the former group and recall of memory B cells from natural infection.

In our study naïve subjects experienced significantly increased spike antibody levels against the SARS-CoV-2 reference strain, SARS-CoV-2 variants, and the human endemic coronaviruses after both doses of vaccine. Previously infected subjects after dose 2, by contrast, saw modest improvement in antibodies against SARS-CoV-2, but antibody levels were stable or declining against HCoV. HCoV memory B and T cells have been implicated in the early response to SARS-CoV-2 exposure (Sokal et al., 2021) and likely explain the induction of HCoV antibodies in infection/vaccination after the first dose in both the previously infected and the naïve. As has been shown with Zika and Dengue viruses (Montoya et al., 2018; , which are closely related flaviviruses, transient cross-reactive antibodies develop in the acute phase (Dispinseri et al., 2021 ) and tend to fade as immune responses mature. Nonetheless, cross-reactive HCoV antibodies J o u r n a l P r e -p r o o f targeting conserved regions were reported to be boosted in some hospitalized patients (Anderson et al., 2021; Guo et al., 2021; Song et al., 2021) and have been associated with the development of neutralizing antibodies (Dispinseri et al., 2021) .

Reliable serological assays to monitor community transmission of SARS-CoV-2 and its variants, and to support post-acute SARS-CoV-2 (PASC) studies are urgently needed. After vaccination, spike antigen serology is unsuitable for detecting SARS-CoV-2 infection; in those immunized with one of the currently available mRNA vaccines, or similar, which do not expose the recipient to the totality of viral antigens, serological assays targeting antigens not included in the vaccine may be used to identify evidence of previous infection. Currently antibodies against the nucleocapsid phosphoprotein are used for this purpose, however, our analysis of longitudinal samples shows that nucleocapsid serology displays poor sensitivity over time ( Figure S1E ). SARS-CoV-2 non-structural proteins such as open reading frame ORF-8 and ORF-3b (Alkhansa, Lakkis and El Zein, 2021; Barik, 2021) have been identified as alternate antibody targets, which in combination may improve sensitivity for detecting previous SARS-CoV-2 infection. These and other non-spike viral epitopes (Lorenzo et al., 2021) constitute a promising strategy to distinguish past SARS-CoV-2 infection from vaccination.

Our data shows a significant lack of neutralizing antibodies in naïve subjects after full vaccination, and a more limited but concerning lack of neutralizing antibodies in some previously infected individuals. In contrast to what has previously been reported, we find that previously infected individuals may benefit from two doses of the currently available mRNA vaccines. Overall, robust binding antibodies are developed after complete vaccination; however, the neutralizing antibody response to mRNA vaccination is highly variable among individuals. In general neutralizing antibody effectiveness against the variant strains, including the currently dominant Delta variant, is moderately reduced compared to the vaccine referent strain. In a subset of individuals categorized as "group 2", J o u r n a l P r e -p r o o f our data does not show improving neutralizing antibodies against circulating variants with repeated vaccine doses with the conventional 3-to 4-weeks regimen. Combined with the overall weak neutralizing antibody responses in group 1 after complete vaccination, this suggests that booster vaccinations, possibly modified for the variants, may be called for in the future. We also find that nucleocapsid IgG wanes over time and is therefore limited as an assay for previous infection with SARS-CoV-2.

Study limitations include the inclusion of subjects receiving only mRNA vaccines, and variability in the time interval between vaccine administration and sample collection among participants. Our cohort's previously SARS-CoV2 infected participants were unlikely to have been infected with one of the variants, and to our knowledge none of the previously infected subjects in our study could have been infected with the currently circulating Delta or Omicron variants. Study participants included primarily young, healthy adults; chronically ill, immunocompromised, and those at the extremes of age are not represented in our study. Our data represent interim values and the durability of vaccine-induced antibody response >6 months after vaccination requires further investigation. Cellular immunity is also clearly very important in the defense against infection with SARS-CoV-2; information regarding T-cell responses to infection and vaccination is not included in the current paper, but is planned for future study. 

The authors declare no competing interests. Subjects were drawn from the workforce of the Emergency Department at George Washington University Hospital and included about 200 healthcare providers.

Every member of this group was invited, including all genders and ethnicities represented among eligible subjects. Anyone who expressed interest was enrolled, and no individual/group was excluded.

One or more of the authors of this paper self-identifies as an underrepresented ethnic minority in science or a member of the LGBTQ+ community. Median, interquartile range (IQR), and the nonparametric Spearman correlation coefficient (rs) are shown for each group. Group stratification by neutralizing antibodies (Group 1, undetectable after dose 1 and remained undetectable or became detectable after dose 2; Group 2, declined between doses 1 and 2; Group 3, improved between doses 1 and 2) are shown. Analysis of vaccine induced antibodies by age within group 1 is presented in Figure S4 . IgG antibodies to full spike proteins from seasonal CoV were measured by ELISA using serially diluted longitudinal sera from 16 naïve (black line) and 11 previously infected (red line) individuals collected ~6 months before dose 1, after dose 1 (3-28 days) and after dose 2 (20-66 days). For comparison, SARS-CoV-2 spike IgG levels in 24 naïve (black line) and 19 previously infected (red line) individuals are presented. Binding antibody titers are expressed as area-under-the-curve (AUC). Wilcoxon-nonparametric paired test was performed to determine if antibody response to SARS-CoV-2 and HCoVs spike proteins between baseline and after doses are different in a subset of previously infected (A-E) and naive (F-J) individuals. The test result revealed that the antibody development between baseline J o u r n a l P r e -p r o o f and after vaccination in naïve and previously infected individuals is statistically significant. The p-value summary from the Wilcoxon test is shown above the scatter plot. p < 0.0001 (****), 0.0002 (***), 0.0021 (**), 0.0332 (*), 0.1234 (ns). (K) Change in spike antibody levels (optical density) between pre-vaccine and after vaccination in previously infected (n=19) and naïve individuals (n=44). Each dot represents a single donor at a time point. The median is shown as a dotted line. 

Further information and requests for resources and reagents should be directed to and will be fulfilled by the Lead Contact, Dr. Lakshmanane Premkumar (prem@med.unc.edu) .

This study did not generate new unique reagents.

The published article includes all datasets generated or analyzed during this study. Any additional information required to reanalyze the data reported in this paper is available from the lead contact upon request. This study did not generate/analyze computer codes or algorithms.

In this study, a total of 424 venous blood samples were collected from 237 unique ED HCP participants 

Emails were sent to all GWUH ED HCP personnel through an ED staff listserv. Additionally, in order to reach those not on the listserv, notifications were sent out through GWUH's ED nurse/technician scheduling system and fliers were placed in break rooms with QR codes connecting to patient sign-up forms. Participation days and times overlapped nurse and technician shift changes in order to encourage on-going and off-going staff to participate. All ED HCP personnel who chose to participate in this study provided written informed consent. All personnel who consented to participate were included in the study.

All participants were asked to complete a questionnaire about demographics (age, gender, race/ethnicity, home city), ED HCP occupation, non-ED HCP affiliations (e.g. also work in the ICU), (Table S1) , and assessed symptomology experienced by study participants following each vaccine dose. The number ( Figure S2 ) and types of symptoms ( Figure S3) were assessed using simple descriptive statistics and then stratified by prior SARS-CoV-2 exposure (naïve or pre-exposed).

Venous blood samples were collected from each participant during each round of testing. 10 ML of blood was drawn into an SST tube, and refrigerated overnight to allow for serum separation.

Subsequently the serum was drawn off into a 2 ML Eppendorf tube and stored at -80° C for subsequent use. We determined the serostatus of the vaccine recipients into previously infected and naïve ( Figure   S1 ) by combining the RT-PCR test results reported elsewhere and the serological assays described in the Methods section. 

The expression and production of halo-tagged SARS-CoV-2 and the four human endemic CoV RBD antigens from mammalian cells were previously described (Premkumar et al., 2020) . The halo-tagged SARS-CoV-2 NTD antigen (16-305 amino acids, Accession: P0DTC2.1) was designed and expressed in mammalian Expi293 cells as described for RBD antigens. RBD and NTD antigens were sitespecifically biotinylated using Halotag PEG biotin ligand (Promega), following the manufacturer's protocol. For producing SARS-CoV-2 spike protein trimer, a codon-optimized gene was synthesized to encode for a prefusion-stabilized SARS-CoV-2 spike protein (16-1208 amino acids, Accession:

P0DTC2.1) with an N-terminal human serum albumin secretion signal peptide and C-terminal T4 foldon trimerization domain, TEV protease cleavage site, His8 tag, and the twin-strep tag. The prefusionstabilized SARS-CoV-2 construct contains two consecutive proline substitutions in the S2 subunit as described before (Walls et al., 2020; Wrapp et al., 2020) . The synthetic gene was cloned between KpnI and XhoI sites of the mammalian expression plasmid pαH. SARS-CoV-2 spike protein was expressed as described for RBD and NTD antigens in Expi293 cells and purified from mammalian cell culture supernatant using Strep-Tactin immobilized affinity resin (IBA Lifesciences). The bacterial expression construct for full-length SARS-CoV-2 nucleocapsid was a gift from Nicolas Fawzi (Addgene plasmid # 157867 ; http://n2t.net/addgene:157867 ; RRID:Addgene_157867) (Perdikari et al., 2020) . The MBP fused nucleocapsid protein was expressed and purified from BL21(DE3)PlysS using Ni-NTA affinity chromatography as described before . The 

We utilized a SARS-CoV-2 luciferase reporter virus (nLuc) to assess neutralizing antibody activity (Hou et al., 2020) . Vero E6 cells were plated at 2x10 4 cells/well in a black 96-well clear bottom plate (Corning).

Heat-inactivated serum was diluted 1:20 initially, followed by a 3-fold dilution series up to eight dilution spots in DMEM supplemented with 5% FBS. Diluted serum was incubated in a 1:1 ratio with SARS-CoV-2-nLuc to result in 75 PFU virus per well. Serum-virus complexes were incubated at 37°C with 5% CO2 for 1 hour. Following incubation, serum-virus complexes were added to the plated Vero E6 cells and incubated for 48 hours at 37C with 5% CO2. After incubation, luciferase activity was measured with the Nano-Glo Luciferase Assay System (Promega) according to the manufacturer specifications.

Neutralization titers (EC50) were defined as the dilution at which a 50% reduction in RLU was observed relative to the virus (no antibody) control. 

Wells of a high-binding microtiter plate (Greiner Bio-One cat # 655061) were coated with 50 μL anti-MBP (New England Biolabs) at 3 ug/mL in TBS pH 7.4, and then blocked with 100 μL of blocking solution (3% non-fat milk in TBST). The plate was washed three times using wash buffer (TBS containing 0.2% Tween 20). 50 μL of 2ug/mL MBP fused full-length nucleocapsid protein and MBP proteins in blocking solution were added to respective wells. The plates were incubated for 1 hour at 37°C. The plates were washed 3 times, then 50 μL of heat-inactivated serum at 1:40 dilution was added to wells containing full-length N protein and MBP proteins were added respectively and further incubated for 1 hour at 37°C. The plates were washed with wash buffer, then 50 μL of alkaline phosphatase-conjugated secondary goat anti-Human anti-IgG (Sigma Cat), anti-IgA (Abcam), and anti-IgM (Sigma) at 1:2500 dilution was added and incubated for 1 hour at 37°C. The plate was washed, and 50 μL p-Nitrophenyl phosphate substrate (SIGMA FAST) was added to the plate and absorbance J o u r n a l P r e -p r o o f measured at 405 nm using a plate reader (Molecular Devices SpectraMax ABS Plus Absorbance ELISA Microplate Reader). Appropriate control sera were included in the study.

Characteristics of the sample were summarized using simple descriptive statistics. To describe the magnitude and spread of full spike and RBD binding IgG, IgM, and IgA titers, we generated jittered dot plots stratified by antibody isotype, time of sampling (post dose 1 and post dose 2), and prior exposure to SARS-CoV-2. Line graphs stratified by time of sampling were used to describe trends in change in antibody levels between doses. The strength of the correlations between spike RBD and spike NTD titers, between spike RBD and full Spike titers, between spike binding antibody titers and SARS-CoV-2 live virus neutralization titers, and between SARS-CoV-2 live virus neutralization titers and ACE2

blocking Ab percent, were evaluated using a two-tailed Spearman's rank correlation in Prism 9.

Neutralizing antibody responses were grouped into Group 1 (undetectable after dose 1 and remained undetectable or became detectable after dose 2), Group 2 (declined between doses 1 and 2), and

Group 3 (improved between doses 1 and 2), and Spearman's coefficient was estimated to assess correlations between neutralizing and binding antibody titers, stratified by vaccine dose. Crossreactivity between WIV04 and three SARS-CoV-2 variants (B.1.1.7, B.1.351, and P.1), and crossreactivity between SARS-CoV-2 and other endemic human coronaviruses was compared using stratified description of antibody titers and kinetics following each vaccine dose.

Effectiveness of the

Vaccine against the B.1.1.7 and B.1.351 Variants'

Mutational analysis of SARS-CoV-2 ORF8 during six 10

Collaboration between the Fab and Fc contribute to maximal protection against SARS-CoV-2 following NVX-CoV2373 subunit vaccine with Matrix-M TM vaccination

Seasonal human coronavirus antibodies are boosted upon SARS-CoV-2 infection but not associated with protection

SARS-CoV-2 vaccines: Lights and shadows

Systematizing the genomic order and relatedness in the open reading frames (ORFs) of the coronaviruses', Infection, Genetics and Evolution

An anti-SARS-CoV-2 non-neutralizing antibody with Fc-effector function defines a new NTD epitope and delays neuroinvasion and death in K18-hACE2 mice', bioRxiv

Anti-SARS-CoV-2 antibody levels are concordant across multiple platforms but are not fully predictive of sterilizing immunity', medRxiv

Distinct Features and Functions of Systemic and Mucosal Humoral Immunity Among SARS-CoV-2 Convalescent Individuals

COVID vaccine boosters: the most important questions

Systemic and mucosal antibody responses specific to SARS-CoV-2 during mild versus severe COVID-19

Anti-SARS-CoV-2 receptor binding domain antibody evolution after mRNA J o u r n a l P r e -p r o o f vaccination

Antibody Responses in COVID-19: A Review

Age-related immune response heterogeneity to SARS-CoV-2 vaccine BNT162b2'

Distribution of IgA1-, IgA2-, and J chain-containing cells in human tissues

Comprehensive assessment of humoral response after Pfizer BNT162b2 mRNA Covid-19 vaccination: A three-case series

Neutralizing antibody responses to SARS-CoV-2 in symptomatic COVID-19 is persistent and critical for survival

SARS-CoV-2 specific antibody and neutralization assays reveal the wide range of the humoral immune response to virus

Evidence for antibody as a protective correlate for COVID-19 vaccines

Antibody responses to the BNT162b2 mRNA vaccine in individuals previously infected with SARS-CoV-2'

Serology Testing Demonstrates That Antibodies to SARS-CoV-2 S1-RBD Correlate with Neutralization of Virus Infection of Vero E6 Cells

The dichotomous and incomplete adaptive immunity in COVID-19 patients with different disease severity', Signal transduction and targeted therapy

Development of an inactivated vaccine candidate for SARS-CoV-2

Antibody Response to the BNT162b2 mRNA COVID-19 Vaccine in Subjects with Prior SARS-CoV-2 Infection

Distinct antibody and memory B cell responses in SARSCoV-2 naïve and recovered individuals following mRNA vaccination

Waning Immunity after the BNT162b2 Vaccine in Israel

Antibodies elicited by mRNA-1273 vaccination bind more broadly to the receptor binding domain than do those from SARS-CoV-2 infection

Comprehensive mapping of mutations in the SARS-CoV-2 receptor-binding domain that affect recognition by polyclonal human plasma antibodies

High Levels of Common Cold Coronavirus Antibodies in Convalescent Plasma Are Associated With Improved Survival in COVID-19 Patients

Cross-reactive antibody against human coronavirus OC43 spike protein correlates with disease severity in COVID-19 patients: a retrospective study

SARS-CoV-2 D614G variant exhibits efficient replication ex vivo and J o u r n a l P r e -p r o o f transmission in vivo

Antibody Responses to SARS-CoV-2 mRNA Vaccines Are Detectable in Saliva

Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection

Correlates of vaccine-induced protection against sars-cov-2', Vaccines

Considerations in boosting COVID-19 vaccine immune responses', The Lancet

Are booster shots coming?

Previously infected vaccinees broadly neutralize SARS-CoV-2 variants', medRxiv : the preprint server for health sciences

The Role of Host Genetic Factors in Coronavirus Susceptibility: Review of Animal and Systematic Review of Human Literature

Immunoinformatics and Pepscan strategies on the path of a peptide-based serological diagnosis of COVID19

Sex Disparities and Neutralizing-Antibody Durability to SARS-CoV-2 Infection in Convalescent Individuals', mSphere

First-dose mRNA vaccination is sufficient to reactivate immunological memory J o u r n a l P r e -p r o o f to SARS-CoV-2 in recovered COVID-19 subjects

N-terminal domain antigenic mapping reveals a site of vulnerability for SARS-CoV-2', Cell

Correlation between universal BCG vaccination policy and reduced mortality for COVID-19', medRxiv

Changing composition of SARS-CoV-2 lineages and rise of Delta variant in

Longitudinal analysis of antibody cross-neutralization following zika virus and dengue virus infection in Asia and the Americas'

Cross-Reactive Neutralizing Antibody Responses Elicited by SARS-CoV-2 501Y.V2 (B.1.351)'

Development of potency, breadth and resilience to viral escape mutations in SARS-CoV-2 neutralizing antibodies.', bioRxiv : the preprint server for biology

COVID-19 infection among emergency department healthcare providers in a large tertiary academic medical center following the peak of the pandemic

Dynamics of antibody response to BNT162b2 vaccine after six months: a longitudinal prospective study

Markers of polyfunctional sars-cov-2 antibodies in convalescent plasma

Original antigenic sin": A potential threat beyond J o u r n a l P r e -p r o o f the development of booster vaccination against novel SARS-CoV-2 variants

Antibody response to first and second dose of BNT162b2 in a cohort of characterized healthcare workers

Immunogenicity of standard and extended dosing intervals of BNT162b2 mRNA vaccine

Durability of mRNA-1273 vaccine-induced antibodies against SARS-CoV-2 variants

SARS-CoV-2 nucleocapsid protein phase-separates with RNA and with human hnRNPs

Mounting evidence for immunizing previously infected subjects with a single dose of SARS-CoV-2 vaccine

Mapping Neutralizing and Immunodominant Sites on the SARS-CoV-2 Spike Receptor-Binding Domain by Structure-Guided High-Resolution Serology

Development of Envelope Protein Antigens To Serologically Differentiate Zika Virus Infection from Dengue Virus Infection

Development of envelope protein antigens to serologically differentiate zika virus infection from dengue virus infection

The receptor binding domain of the viral spike protein is an immunodominant and highly specific target of antibodies in SARS-CoV-2 patients

COVID vaccines and safety: what the research says

Confronting the Delta Variant of SARS-CoV-2

Defining the features and duration of antibody responses to SARS-CoV-2 infection associated with disease severity and outcome

mRNA vaccination compared to infection elicits an IgG-predominant response with greater SARS-CoV-2 specificity and similar decrease in variant spike recognition', medRxiv

COVID-19 Vaccines vs Variants-Determining How Much Immunity Is Enough

Adaptive immunity to SARS-CoV-2 and COVID-19

Maturation and persistence of the anti-SARS-CoV-2 memory B cell response

Cross-reactive serum and memory B-cell responses to spike protein in SARS-CoV-2 and endemic coronavirus infection

Optimizing immunization protocols to elicit broadly neutralizing antibodies

IgA dominates the early neutralizing antibody response to SARS-CoV-2'

Postvaccination SARS-CoV-2 Infections Among Skilled Nursing Facility Residents and Staff Members

Robust Neutralizing Antibody Responses 6 Months Post Vaccination with BNT162b2: A Prospective Study in 308 Healthy Individuals

Single-dose BNT162b2 mRNA COVID-19

SARS-CoV-2 infection

Robust neutralizing antibodies to SARS-CoV-2 infection persist for months

Structure, Function, and Antigenicity of the SARS-CoV-2 Spike Glycoprotein

A conserved immunogenic and vulnerable site on the coronavirus spike protein delineated by cross-reactive monoclonal antibodies

Enhanced SARS-CoV-2 neutralization by dimeric IgA

Covid-19: People who have had infection might only need one dose of mRNA vaccine

Department of Chemistry and National Institute for Biotechnology in the Negev, Ben-Gurion University of the Negev

Preliminary Analysis of Safety and Immunogenicity of a SARS-CoV-2 Variant Vaccine Booster', medRxiv

Structural and functional ramifications of antigenic drift in recent SARS-CoV-2 J o u r n a l P r e -p r o o f variants

The variants question: What is the problem?

Antibody response to BTN162b2 mRNA vaccination in naïve versus SARS-CoV-2 infected subjects with and without waning immunity

This study was supported by grants from the National Cancer Institute (U54CA260543 to A.M.de, R.S.B, and L.P.) and National Institutes of Health, Allergy and Infectious Diseases (U01AI151788 to A.M.de and L.P). We would like to thank the health care providers and staff at the George Washington